Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy

Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.

Authors

Institutions

Publication Details

Journal
International Journal of Ophthalmology
Published
2026-02-12
DOI
https://doi.org/10.18240/ijo.2026.02.14
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy

Jung Yeon Joo
International Journal of Ophthalmology
Retinal Diseases and Treatments
article

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy

Jung Yeon Joo
article en

Abstract

Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.

International Journal of OphthalmologyVol. 19(2)
Chosun University (KR)
Chosun University
Openalex Percentile: Top 81%
Retinal Diseases and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy — Jung Yeon Joo · International Journal of Ophthalmology (2026) | TGRS Research Map | TGRS